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Abstract 
Polypharmacy is an increasing and global issue affecting primary care. Although 
sometimes appropriate, polypharmacy can also be problematic leading to a range of 
adverse consequences. Deprescribing is the process of supervised withdrawal of an 
inappropriate medication, and has the potential to reduce some of the problems 
associated with polypharmacy. It is a complex and sensitive process. We examine 
the issue of deprescribing from the perspective of UK general practice. 
Key steps in the deprescribing process are a review of medications and 
corresponding indications, consideration of harms, assessment of eligibility for 
discontinuation, prioritisation of medications, and implementation of a stopping plan 
with appropriate monitoring. Patient involvement is a key feature of this process. 
Deprescribing should be considered in the context of end of life care and medication 
safety, but approaches are also required to identify other situations where 
deprescribing is appropriate. GPs are well positioned to facilitate deprescribing, 
usually through formal medication review, with decisions informed by a range of 
other health care professionals. Guidelines are available which help guide these 
processes. A range of studies have explored attitudes towards deprescribing; 
patients are generally supportive of the concept, although clinician views are varied. 
The successful implementation of deprescribing strategies still requires important 
patient and clinician barriers to be overcome, and clinical trial evidence of 
effectiveness and safety are essential. 
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Introduction 
Deprescribing is “the process of withdrawal of an inappropriate medication, 
supervised by a health care professional with the goal of managing polypharmacy 
and improving outcomes”.1  This is particularly relevant to patients with 
polypharmacy (the prescription of multiple medications) because the risk of harm 
caused by medication increases with the number of medications a patient is 
prescribed.2  Stopping or reducing medications requires careful clinical 
consideration, with a need to balance issues such as potential loss of clinical benefit 
and increased patient anxiety, against reductions in medication errors, adverse 
reactions and prescribing burden. To reflect these complexities and sensitivities the 
term ‘deprescribing’ has been adopted rather than simply stopping medicines.  This 
requires similar levels of skill to prescribing in the first place. 
This narrative review examines the issue of deprescribing from the perspective of UK 
general practice. In the UK, the general practitioner (GP) is the first point of contact 
with the health service for most patients, and gatekeeper to specialist services. 
Virtually all UK residents are registered with a GP as part of the state-funded 
National Health Service, and the management of long-term conditions, including 
prescription of long-term medications, is mostly managed in this setting. 
The purpose of this review is to: (i) describe trends in polypharmacy and 
explanations for why it is increasing; (ii) outline the harms associated with over-
treatment; (iii) outline the rationale for deprescribing and different approaches to 
deprescribing within general practice, including the role of the pharmacist; (iv) outline 
the barriers and enablers to deprescribing; and (v) make recommendations for future 
practice.  
 
Trends in polypharmacy 
Polypharmacy is a global issue, affecting developed and developing nations (Table 
1). The prevalence of polypharmacy within the UK is increasing – in Scotland the 
proportion of patients prescribed five or more medications doubled to 20.8% from 
1995 to 2010, and the proportion prescribed ten or more medications tripled to 5.8% 
over the same period (see Table 1).3  A similar picture is seen in England, with 
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national dispensing data showing a 64% increase in the number of medications 
dispensed in primary care from 2001 to 2011.4 
[INSERT Table 1] 
The rise in polypharmacy is being driven by a number of factors. The population is 
ageing, and this in turn is associated with increased multimorbidity (the coexistence 
of multiple long term conditions in one individual). The number of people aged 85 
years or over is set to increase at the fastest rate, more than doubling to 3.6 million 
between 2014 and 2039.5 Multimorbidity has become the norm in UK general 
practice, with over half of adults having two or more long term conditions and over 
three-quarters of general practice consultations involving patients with 
multimorbidity.6  Polypharmacy has been shown to have a clear association with 
both increasing age and number of long-term conditions7-9. A further factor is the 
trend to prescribe preventative medication to asymptomatic patients to prevent future 
disease and mortality.4 In the UK, this is partly due to a primary care payment-for-
performance system (the Quality and Outcomes Framework, QOF) setting 
incentivised targets for GPs to treat common long-term conditions.  The number of 
treatment guidelines has also increased in recent years, with most guidelines 
promoting commencement of new treatment and very few promoting stopping 
medications. Importantly, the evidence-base for many of these guidelines is derived 
from trials which often exclude elderly patients and patients with multimorbidity, 10  
and the recommendations seldom consider the cumulative impact of receiving 
treatment for more than one long-term condition or provide information about how to 
weigh up the risks and benefits of treatment.11  Finally, UK g neral practice employs 
a system known as repeat prescribing, which enables patients to reorder long-term 
medications without requiring a further assessment by a clinician for long periods of 
time, and may contribute to polypharmacy. Although reviews of such prescriptions 
are usually undertaken at least annually, the effectiveness of these ‘repeat’ reviews 
in terms of rationalising treatment in the older, multimorbid population has been 
questioned.12  
 
Harms of polypharmacy 
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5 
Before outlining the harms of overprescribing, it is important to distinguish 
problematic from appropriate polypharmacy.  Appropriate polypharmacy describes 
the necessary use of multiple evidence-based medications to improve the quality of 
a person’s life and extend their life.4  We have previously demonstrated that the 
adverse consequences of polypharmacy are dependent on clinical context, and have 
cautioned against assumptions that polypharmacy is always harmful and represents 
poor care.13 14 There is also clear evidence for the benefits of some multiple 
medications, for example in the context of cardiovascular risk reduction.15  
Problematic polypharmacy describes the situation where the risk of taking multiple 
medications outweighs the benefit.4  There is strong evidence that increased 
numbers of medicines are associated with various adverse consequences, much of 
this evidence coming from primary care. This includes a greater risk of high risk 
prescribing3, medication errors16, adverse drug reactions17,  poor adherence18,  and 
impaired quality of life.19 This is particularly relevant in frail and older people, in 
whom pharmacokinetic and pharmacodynamic changes may increase vulnerability 
to, and magnitude of, medication side effects.20 Furthermore these people may have 
cognitive impairment, visual impairment or loss of dexterity, making management of 
complex medication regimens more difficult and potentially more prone to error and 
hazard.  
The burden of treatment - the effort of looking after one’s health and the impact that 
this has on general wellbeing21 - is also worth considering.  Patients are responsible 
for co-ordinating their appointments, self-monitoring their conditions and finding ways 
to incorporate complex medical regimens into their everyday life.  Taking a lot of 
drugs is a challenge for patients, particularly those from lower socio-economic 
groups who may have lower numeracy and literacy levels.22  Patients with 
multimorbidity are often required to attend separate appointments for each of their 
long term conditions and are at particular risk of treatment burden.  Mair and 
colleagues argue for ‘minimally disruptive medicine’, whereby individual preference, 
multimorbidity and treatment burden are at the centre of clinical decisions.23 
 
Rationale for deprescribing and current approaches 
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Deprescribing has the potential to reduce pill burden, side effects, adverse drug 
events, medication errors, drug-drug interactions, and in doing so decrease health 
service utilisation and morbidity, and improve quality of life and other health 
outcomes for patients.  Interestingly, however, although the harms of inappropriate 
polypharmacy are reasonably well established, there is a lack of direct evidence for 
the benefits of deprescribing in the general practice setting. 
 
The deprescribing process 
Scott and colleagues have outlined five steps in the deprescribing process: firstly, 
find out what medications the patient is taking and the indications; secondly, 
consider the overall risk of drug-induced harm; thirdly, assess each medication in 
terms of eligibility to be discontinued (e.g. lack of indication, unacceptable treatment 
burden, harm outweighs benefit); fourthly, prioritise which medications to stop ; and 
finally, implement a plan to stop the medication and monitor the consequences.24 An 
earlier version of this model has been found to have face validity by hospital 
clinicians,25 but it is also highly likely to be appropriate to the general practice setting.  
A review by Reeve and colleagues found that, out of ten published articles 
describing the deprescribing process or related elements, four included all five of 
these principles.26  The review also found evidence supporting the different 
principles, although this was limited in nature.  For particular medications, such as 
selective serotonin reuptake inhibitors, there is a risk of discontinuation reactions.  
The final stage of the deprescribing process – planning how to stop the medication 
and arranging follow-up – is likely to reduce this risk.  
The Royal Pharmaceutical Society27 outlines four guiding principles for medication 
optimisation (see Figure 1) – referred to in NICE Guidelines on Medicines 
Optimisation. These principles are understanding the patient’s perspective, views 
and preferences; assessing the evidence base and cost-effectiveness of treatments; 
ensuring medicine safety; and establishing medication optimisation as part of routine 
practice.   Although this model is not specifically focused on deprescribing, each of 
the principles is highly relevant to this process.  In particular, patient involvement in 
decisions to change medications is a key feature. 
[INSERT Figure 1] 
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A study in the South of England set out to explore the relationship between shared-
decision-making and patient satisfaction, adherence and perceived practitioner 
empathy.28  Prescribing decisions were common, occurring in 79% of consultations, 
but patients were given treatment options in only 21% of prescribing decisions and 
the patient’s treatment preference was elicited in only 18% of decisions.  Prescribing 
pharmacists were more likely to ask about patient preference than GPs and nurse 
prescribers.  In consultations where more time was spent discussing treatment 
options, patient reported satisfaction, adherence and practitioner empathy was rated 
more highly, although the issue of deprescribing was not specifically studied.   
 
Which patients? 
Deprescribing should be routinely considered in the context of preventative 
medication use in patients with reduced life expectancy29, and particularly so in 
palliative cancer care.30 This is especially important given that 20% or more of 
palliative care patients are in receipt of inappropriate medications,30 and is very 
pertinent in the general practice setting, with GPs providing end of life care to over 
40% of patients.31 Increasingly it is recognised that people with non-cancer diseases 
such as severe COPD and heart failure should also be assessed for stepping down 
treatment and end of life considerations.32 People in the care home setting are also 
likely to be at a point where deprescribing is indicated.  Nevertheless, deprescribing 
is relevant in other clinical situations as well, particularly given that over a third of 
older general practice patients experience inappropriate prescribing.33  Objective 
measures of inappropriate prescribing (e.g. Beers’ criteria34 and the STOPP/START 
criteria35) are a key primary care patient safety tool36, and thus an important potential 
means of identifying individuals in whom deprescribing may be of value.  A 
pragmatic approach of using a straightforward medication count potentially 
supplemented with indicators of problematic prescribing has been suggested in a 
King’s Fund report.4  There is, however, a need for better approaches to identify 
situations where deprescribing is appropriate due to issues other than safety or end-
of-life care. 
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8 
Which health care professional? 
The GP is ideally positioned to facilitate deprescribing, as they have access to the 
patient’s full medical history (including current and drug history, diagnoses and 
investigations) to help inform medical decisions, and often an established 
relationship with the patient that imbues trust and supports shared decision 
making.37  Decisions to stop medications are complex, particularly given that patients 
prescribed multiple medications often have a complex of long term conditions.  As 
such, GPs who achieve good continuity of care with their patients are perhaps best 
placed to make deprescribing decisions.  Indeed, we have found evidence that there 
is an association between improved continuity of care and decreased total 
prescribing burden (Payne RA, unpublished data).In current practice, a formal 
medication review with a GP is likely to provide the best opportunity to enact 
decisions around deprescribing, with more dedicated time than is available during 
the opportunistic circumstances of other appointment types. There is no single 
agreed approach to the medication review process or the points that should be 
covered when considering stopping medicines.  However, an example of some 
potential issues that might be considered is shown in the Box. GPs seem readily 
able to add to medication but stopping treatments is often not considered at the 
same time; maybe it would be best if all new medication was only commenced as a 
trial of therapy and substitution always considered as an alternative to addition. In a 
US study of primary care physician medication review, discontinuation of medicines 
was only reported by a fifth of patients.38  Evidence from hospital practice also 
suggests that recommendations to stop medications are not acted upon39, and 
evidence from a community based older population found that a quarter of 
medications that had been stopped were reintroduced within the following 12 
months.40 
 
[INSERT Box] 
GP deprescribing decisions can also be informed by a range of other health care 
professionals, who may have more time than the GP to dedicate to a prescribing 
review.  Primary care nurses often have a central role in managing common long-
term conditions in general practice, and Brandt has discussed nurse-led approaches 
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to deprescribing, which are highly relevant to general practice.41  Community 
pharmacists also have a valuable role with respect to deprescribing. One particular 
intervention type is medication use reviews (MURs), structured adherence-centred 
reviews particularly focused on long-term conditions in patients subject to 
polypharmacy. There is evidence that clinical pharmacist medication reviews can 
reduce numbers of prescribed drugs42, and the PINCER trial showed that a 
pharmacist-led intervention in general practice could reduce hazardous prescribing.43 
However, the specific evidence for MURs by community pharmacists is limited.44  
There has been a recent call to increase the role of clinical or practice pharmacists to 
work directly in g neral practice to address unmet workforce demands45,and pilot 
work is being undertaken to explore this in England.46  Finally, although the 
continuing provision of medication for long-term problems is usually managed by the 
GP, hospital clinicians, and in particular clinical pharmacists and generalist 
physicians (e.g. geriatricians), can contribute to deprescribing, and hospital-based 
interventions to identify and stop unnecessary medication for elderly inpatients have 
indeed been found to be effective. 47 
 
Guidelines 
In the UK, clinical guidance has been published by both Wales and Scotland, 
detailing approaches to polypharmacy of which medication review is considered 
central.48 49  Both of these identify a number of important clinical areas to focus on, 
chosen largely on the basis of expert opinion.  Other priorities have been set by 
survey work and expert panel opinion undertaken by Farrell and colleagues which 
found key classes of medications to include benzodiazepines, atypical 
antipsychotics, statins, tricyclic antidepressants and proton pump inhibitors50. 
Lindsay et al have also developed and validated a deprescribing guideline 
specifically for palliative cancer patients.51   
Treating the patient as central to the medication optimisation process is a key 
principle outlined by the National Institute for Health and Care Excellence.2  Conklin 
and colleagues have published a protocol for a study to investigate improving 
implementation of deprescribing guidelines.52 
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Trial evidence 
Despite the existence of systems that theoretically support deprescribing as well as 
the development of clinical guidance, trial evidence for deprescribing processes and 
improved outcome is relatively lacking in primary care.  An Australian feasibility study 
by Reeve et al, based on the five-step process outlined above, tested a patient-
centred intervention to deprescribe proton pump inhibitors (PPIs) for adults with 
polypharmacy.53  The study found the process was acceptable and could reduce 
inappropriate PPI use in a small proportion of patients, but there were important 
barriers to implementation.  A Canadian trial of a community-pharmacy based 
patient-education intervention demonstrated effectiveness at reducing 
benzodiazepine use in older adults54.  A systematic review of medication withdrawal 
found four trials supporting the safe reduction of diuretic therapy (albeit not in heart 
failure) and some improvements following reduction in psychotropic medication.55  
Antipsychotic withdrawal has a so been found to be safe in the majority of people 
with dementia.56  Despite hypertension being the most prevalent long-term condition 
in older people, trials of antihypertensive withdrawal are lacking, although 
prospective observational studies suggest many patients remain normotensive.55 
 
Barriers and facilitators to deprescribing 
A range of studies have explored patients, carers and clinicians attitudes towards 
deprescribing.  
 
Patient and carer views 
Certainly, overall, patients are supportive of the idea of deprescribing.  The term 
deprescribing may not be acceptable to some patients, however, who might 
associate it with money saving.57  A survey of Australian care homes found 40% of 
residents expressed a wish to reduce their medications with over three-quarters 
willing to do so if deemed possible by their doctor.58  A further study of older 
ambulatory-care adults found over 90% were willing to stop one or more 
medications.37  A systematic review found that patient-reported barriers to 
deprescribing included disagreement over the appropriateness of stopping 
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medication, lack of a process to stop medication and fear of stopping medications.59  
Enablers to deprescribing were agreement that it was appropriate to stop the 
medication, a system to stop or taper down the medication, and a dislike of taking 
medications. 
 
Clinician views 
Anderson et al conducted a systematic review and thematic synthesis of qualitative 
studies that explored prescribers’ perceived barriers and enablers to minimising 
potentially inappropriate medications for adults with long term conditions.60  Twenty-
one studies were included and most focused on the views of primary health care 
physicians towards managing elderly patients.  Factors that influenced decisions of 
whether or not to deprescribe were grouped as being intrinsic to the prescriber (e.g. 
their beliefs, attitudes, knowledge, skills and behaviour) or extrinsic to the prescriber 
(e.g. the patient, work setting, health system and cultural factors). 
A substudy of the ECSTATIC trial investigated attitudes to stopping preventive 
cardiovascular medication.61  GPs reported that their decision to stop unnecessary 
medication was influenced by their perception that specialists would disapprove of 
them stopping medications.  A study in New Zealand investigated GPs’ views on 
deprescribing in multimorbid elderly patients.62  Considerable variation in opinions on 
deprescribing were observed between GPs, and the authors proposed better 
guidelines for stopping medicines in order to reduce such variation. 
A survey of physicians specialising in care of the elderly attitudes to deprescribing 
found that limited life expectancy, cognitive impairment and pill burden were 
important drivers to deprescribing.63   
In a recent South Australian study, GPs ranked evidence for deprescribing and 
patient/family communication as the most important factors to consider when 
considering stopping medications. This differed from other health care professionals, 
with nurses prioritising doctors’ receptivity to deprescribing and patient advocacy, 
and pharmacists prioritising clinical appropriateness and identifying patients’ goals.64  
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Special groups: care home residents, palliative care patients and the very elderly 
A study in Australia sought to explore the views of care home residents, relatives 
and care professionals towards polypharmacy and deprescribing.65  Care home 
residents reported that taking lots of medication was burdensome but they lacked 
understanding of what the medications were for and of potential harms caused by 
the medication.  They trusted their GP and were willing to accept changes, including 
stopping medications, if they were suggested by their GP.  Barriers to deprescribing 
reported by GPs included a lack of time, poor medical record keeping for care home 
residents, limited training of care home workers, and difficulties with collaborating 
with care home workers and pharmacists.  
A qualitative study in the United States to explore palliative care patient’s, carers and 
health care professionals views on stopping unnecessary medications, such as 
statins, found that patients were accepting of the concept of stopping preventative 
medications once they had come to terms with the fact that their illness was life-
limiting.66  The authors concluded that it was important to explore patient’s 
expectations of their illness and treatment, and to time discussions about stopping 
medications appropriately. 
A study of Dutch GP’s views on deprescribing in the very elderly found that GP’s 
broadly categorized medications into ‘symptomatic medication’ and ‘preventative 
medication’.67  Deciding to deprescribe preventative medication was seen as more 
difficult for GPs because there was a lack of guidance about the risk/benefit ratio.  
GPs believed that patients did not have a problem taking multiple medications and 
were worried that by stopping medication, patients would feel that they were giving 
up on them.  They were reluctant to discuss issues about approaching the end of life 
with patients.  Other barriers to deprescribing included having to comply with 
guidelines to increase medications. 
 
Recommendations for the future 
Guthrie et al make several suggestions of how guidelines could better inform 
treatment of people with multimorbidity.68  The first is to increase the number of 
cross-referenced guidelines.  The paper cites an existing National Institute for Health 
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13 
and Care Excellence (NICE) guideline that provides advice on choice of 
antidepressant medication depending on coexistence of physical long term 
conditions and co-prescribing.  A second recommendation is for existing quick 
reference guidelines to contain more information about the magnitude of the likely 
benefit, some information about the potential harm of medication, and an idea of how 
long the patient needs to take the medication to benefit from it.  A final suggestion is 
to improve the evidence base by including elderly patients with multimorbidity in 
clinical trials.  
Although there is good evidence that polypharmacy can be harmful to patients, there 
is a lack of evidence for the benefit of stopping medications, particularly within a 
primary care setting.  Trial evidence for deprescribing is poor.  Further research is 
needed to determine whether stopping potentially inappropriate medications, such as 
antihypertensive medication and proton pump inhibitors, improves health outcomes 
for patients.  There is some evidence that interventions to improve appropriate 
prescribing of medication reduce pill burden but studies have been inadequately 
powered to investigate clinical outcomes, such as health related quality of life and 
health service utilisation. 
In the UK, NICE have recently published a draft guideline on multimorbidity, which 
acknowledges the need to stop medicines as part of developing an individualised 
management plan for people with multimorbidity.69 An accompanying database 
comparing risks and benefits of treatments for common long-term medications has 
also been made available. Such guidance may be of value in empowering GPs to 
deprescribe, but effective implementation of the guidance will be essential. 
 
Conclusion 
Polypharmacy is a major challenge for modern health care systems, driven by aging, 
increasingly multimorbid populations, and with growing adherence to protocol-driven 
practice and the use of evidence-based guidelines which focus on single-diseases. 
Safe approaches for dealing with problematic polypharmacy are essential with 
medication reviews being an important component; deprescribing is one approach to 
rationalisation of medicines to minimise risk and achieve better outcomes. GPs and 
pharmacists are ideally placed to carry this out. Guidance to support prescribers in 
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the reduction of medications is becoming more readily accessible, which follow a 
number of well-described principles and ensure that patient involvement with shared-
decision making is central to the process. However, clinical trial evidence of 
effectiveness and safety is still required, and there remain numerous patient and 
clinician barriers to the successful implementation of deprescribing strategies. 
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Table 1: International variations in prevalence of polypharmacy in community and primary care settings 
Study 
 
Setting Age of 
participants 
Number of 
medications 
Rates of 
polypharmacy 
Notes 
Hovstadius, 20089 
 
Sweden, primary 
care 
 
Total population 
 
≥ 5 
≥ 10 
11.1% 
2.4% 
Rates of polypharmacy 
increased with age 
60-69 years 
 
≥ 5 
≥ 10 
21.4% 
4.1% 
≥ 80 years 
 
≥ 5 
≥ 10 
52.3% 
15.5% 
Qato, 200870 US, community 
 
57 to 85 years ≥ 5 
 
29% Rates of polypharmacy 
increased with age and 
female gender 
Dong, 201071 Rural China, 
primary health 
care clinics 
 
Total population ≥ 5 5.8% Village doctor workload and 
government subsidies 
influenced the rates of 
polypharmacy. 
Richardson, 
201272 
Ireland, 
community 
≥ 50 years 
 
≥ 5 
≥ 10 
19% 
2% 
Rates of polypharmacy was 
greatest in those with self-
reported hypertension, 
hypercholesterolaemia, 
arthritis, chronic pain and 
diabetes 
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Oliveira, 201273 Brazil, primary 
care 
≥ 60 years ≥ 4 64.5% Small study with 142 
participants 
Payne7, 2014 Scotland, primary 
care 
 
Total population 
 
4-9 
≥ 10 
16.9% 
4.6% 
Polypharmacy increased with 
the number of long term 
conditions. 
60-69 years 
 
4-9 
≥ 10 
28.6% 
7.4% 
≥ 80 years 
 
4-9 
≥ 10 
51.8% 
18.6% 
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Figure 1: Summary of the four principles of medicines optimisation27 
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Box: Practical framework to guide stopping medication74  
General advice 
- Always regard starting a treatment as a trial 
- Always regard stopping a treatment as a trial 
- Unless there are significant adverse drug effects there is usually plenty of 
time to 
- stop or taper medicines one after another 
- Consider discussing with other clinicians and develop a clinical 
management plan 
- to aid continuity. 
 
Recognise the need to stop a medicine 
- Any new problems or symptoms? Could these be related to adverse 
effects? 
- Review the patient’s and/or carer’s concerns about the medicine 
- Consider the preferences of the patient (and/or carer) 
- Is there still a clear clinical indication for the treatment (often this may be 
unclear 
- or forgotten) 
- Has the clinical condition of the patient changed? 
- Have the evidence or guidelines changed since a drug was initiated? 
- If more than one medicine can be stopped, which one should be stopped 
first? 
 
Reduce or stop one medicine at a time 
- As much as possible reduce or stop one medicine at a time. If problems 
develop it is then easier to know what the likely cause may be 
- Taper medicines when appropriate – examples where this may be 
particularly important include: opioids, antidepressants, antipsychotics, 
beta-blockers, hypnotics 
- Give patients (and/or carers) advice on any symptoms that might be 
expected when drugs are withdrawn. Often reassurance is all that is needed 
- If in doubt taper, as it is safer 
- For many medicines the first step in tapering is to halve the dose 
- Establish if the patient’s symptoms, conditions or risks can be managed 
with a lower dose or whether the medicine can be stopped completely 
- Once tapering has begun, ask the patient to note any symptoms that may 
suggest a more gradual withdrawal is required. 
 
Check for benefit or harm after each medicine has been stopped 
- Ask the patient if any changes or problems have occurred after a medicine 
has been stopped 
- Beneficial effects may indicate that the decision to reduce or stop the 
medicine was correct 
- If symptoms of the initial condition return and are troublesome, despite 
gradual tapering, then it may be that the medicine cannot be stopped 
completely. 
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